Scarica l'app Stockscreener
100.98
2.38%
-2.18
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$103.16
Aprire:
$102.02
Volume 24 ore:
188.15K
Relative Volume:
0.23
Capitalizzazione di mercato:
$4.59B
Reddito:
$1.33B
Utile/perdita netta:
$97.31M
Rapporto P/E:
49.70
EPS:
2.0317
Flusso di cassa netto:
$260.44M
1 W Prestazione:
-2.08%
1M Prestazione:
+16.28%
6M Prestazione:
+60.23%
1 anno Prestazione:
+87.64%
Intervallo 1D:
$100.59
$102.95
Intervallo di 1 settimana:
$100.57
$103.56
Portata 52W:
$47.31
$109.57
Haemonetics Corp Stock (HAE) Company Profile
Nome
Haemonetics Corp
Settore
Industria
Telefono
(781) 848-7100
Indirizzo
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
100.94 | 4.69B | 1.33B | 97.31M | 260.44M | 2.0317 |
ABT
Abbott Laboratories
|
103.79 | 182.09B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
91.52 | 117.54B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
270.72 | 105.63B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
43.21 | 65.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.31 | 49.67B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-15 | Downgrade | Needham | Buy → Hold |
| 2025-12-11 | Downgrade | Citigroup | Buy → Neutral |
| 2025-08-11 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | Reiterato | Barrington Research | Outperform |
| 2025-08-08 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-07-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-06-26 | Iniziato | Robert W. Baird | Outperform |
| 2025-02-07 | Downgrade | BofA Securities | Neutral → Underperform |
| 2024-12-06 | Iniziato | JP Morgan | Overweight |
| 2024-11-08 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | Iniziato | CL King | Buy |
| 2024-09-11 | Iniziato | BofA Securities | Neutral |
| 2024-09-10 | Iniziato | BTIG Research | Buy |
| 2024-06-12 | Aggiornamento | Needham | Hold → Buy |
| 2022-10-13 | Iniziato | Mizuho | Buy |
| 2022-01-27 | Downgrade | Needham | Buy → Hold |
| 2021-12-15 | Downgrade | Citigroup | Buy → Neutral |
| 2021-08-17 | Ripresa | Raymond James | Outperform |
| 2021-06-17 | Iniziato | Citigroup | Buy |
| 2021-05-14 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | Aggiornamento | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | Iniziato | Needham | Buy |
| 2019-08-07 | Reiterato | Barrington Research | Outperform |
| 2019-05-14 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | Reiterato | Barrington Research | Outperform |
| 2018-08-09 | Reiterato | Barrington Research | Outperform |
| 2018-02-07 | Reiterato | Barrington Research | Outperform |
| 2018-01-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | Reiterato | Barrington Research | Outperform |
| 2017-08-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | Aggiornamento | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | Aggiornamento | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | Reiterato | The Benchmark Company | Hold |
| 2016-09-20 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | Downgrade | Sidoti | Buy → Neutral |
| 2016-08-02 | Reiterato | Jefferies | Buy |
| 2016-08-02 | Reiterato | The Benchmark Company | Hold |
Mostra tutto
Haemonetics Corp Borsa (HAE) Ultime notizie
Q1 2027 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics Stock Price Forecast. Should You Buy HAE? - StockInvest.us
HAE Maintained by Raymond James -- Price Target Raised to $125 - GuruFocus
Haemonetics Corporation (HAE) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Haemonetics Corporation (HAE) Peer Comparison – Compare with Others - Value Research
Haemonetics (HAE) Stock Looks Reasonable On Cash Flow But Rich On Earnings - simplywall.st
Haemonetics (HAE) Q1 2027 Earnings Call Transcript - AOL.ca
Winners And Losers Of Q2: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & SuppliesSpecialty Stocks - Yahoo Finance
HAE Maintained by Baird -- Price Target Raised to $119.00 - GuruFocus
Haemonetics grows recurring revenues with plasm... - Pluang
Robert W. Baird Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price - MarketBeat
Haemonetics: Worth Speculating On This Recurring Medtech Plasma Model (NYSE:HAE) - Seeking Alpha
26,280 Shares in Haemonetics Corporation $HAE Acquired by Nierenberg Investment Management Company LLC - MarketBeat
Aurora Investment Counsel Acquires New Position in Haemonetics Corporation $HAE - MarketBeat
Haemonetics stock hits 52-week high at 106.64 USD By Investing.com - Investing.com South Africa
HAE Maintains by Barrington Research -- Price Target Raised to $118 - GuruFocus
HAEMONETICS CORP : BARRINGTON RESEARCH RAISES TARGET PRICE TO $118 FROM $95 - Bitget
Haemonetics stock hits 52-week high at 106.64 USD - Investing.com
Barrington Raises Price Target on Haemonetics to $118 From $95, Keeps Outperform Rating - marketscreener.com
Haemonetics Shares Hit New 52-Week High: What's Happening? - Sahm
Is Haemonetics’ (HAE) ESOP Shelf Move Reframing Its Balance Between Growth Investment and Shareholder Dilution? - simplywall.st
Haemonetics Corp (HAE) Shares Surge 15.9% -- What GF Score of 85 Tells Investors - GuruFocus
HAE Maintained by BTIG -- Price Target Raised to $110 - GuruFocus
Haemonetics (HAE) Stock Climbs As Analysts Hike Price Targets - StocksToTrade
Form 8K Haemonetics Corp For: 18 August By Investing.com - Investing.com Australia
Haemonetics Jumps as Investors Cheer Raised Fiscal 2027 Outlook - Quiver Quantitative
HAE Looks 23.1% Overvalued on GF Value™ - GuruFocus
Haemonetics stock surges 16% on CSL Plasma supply deal By Investing.com - Investing.com Australia
Haemonetics stock surges 16% on CSL Plasma supply deal - Investing.com
HAE Looks 21.1% Overvalued on GF Value™ as Stock Surges to $104 - GuruFocus
Haemonetics (NYSE:HAE) Reaches New 12-Month High Following Analyst Upgrade - MarketBeat
Haemonetics (NYSE:HAE) Price Target Raised to $110.00 at BTIG Research - MarketBeat
Haemonetics Announces Non-Exclusive Supply Agreement with CSL Plasma for NexSys PCS Devices - Kalkine Media
HAE Looks 5.9% Overvalued on GF Value™ as Supply Deal with CSL P - GuruFocus
Why is Haemonetics stock surging today? - Investing.com
Why is Haemonetics stock surging today? By Investing.com - Investing.com Australia
Haemonetics announces non-exclusive supply agreement with CSL Plasma By Investing.com - Investing.com Australia
Haemonetics rises after supply deal with CSL - seekingalpha.com
Haemonetics announces non-exclusive supply agreement with CSL Plasma - Investing.com
Haemonetics signs non-exclusive U.S. supply deal with CSL Plasma for NexSys PCS devices - TradingView
Rice Hall James & Associates LLC Makes New Investment in Haemonetics Corporation $HAE - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Haemonetics (HAE) Stock Could Be 49% Below Fair Value On Raised Guidance - Yahoo Finance
Haemonetics (HAE) Earnings Beat Puts Fair Value Back In Focus - Yahoo Finance
Haemonetics (NYSE:HAE) Shines in Quality Investing Screen - ChartMill
5 Insightful Analyst Questions From Haemonetics’s Q2 Earnings Call - Yahoo Finance
John Rogers's Top Q2 2026 Move: Haemonetics Corp at a 1.54% Portfolio Impact - Yahoo Finance
John Rogers's Top Q2 2026 Move: Haemonetics Corp at a 1.54% Port - GuruFocus
HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up - Yahoo Finance
Assenagon Asset Management S.A. Sells 142,292 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corporation (NYSE:HAE) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Haemonetics Corp Azioni (HAE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.21%
0.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):